

Zhen Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10080355/publications.pdf>

Version: 2024-02-01

9
papers

64
citations

1937685
4
h-index

1588992
8
g-index

9
all docs

9
docs citations

9
times ranked

58
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodological quality of machine learning-based quantitative imaging analysis studies in esophageal cancer: a systematic review of clinical outcome prediction after concurrent chemoradiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2462-2481.	6.4	12
2	Internal modulation of proteolysis in vascular extracellular matrix remodeling: role of ADAM metalloproteinase with thrombospondin type 1 motif 5 in the development of intracranial aneurysm rupture. <i>Aging</i> , 2021, 13, 12800-12816.	3.1	5
3	The Presence of Genomic Instability in Cerebrospinal Fluid in Patients with Meningeal Metastasis. <i>Cancer Management and Research</i> , 2021, Volume 13, 4853-4863.	1.9	2
4	One Cycle of Concurrent Chemotherapy vs. Two Cycles of Concurrent Chemotherapy With Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 785022.	2.8	3
5	Immune response pathways enriched in breast cancer samples with brain metastasis. <i>Gland Surgery</i> , 2021, 10, 3334-3341.	1.1	1
6	KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 375-385.	2.5	22
7	Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis. <i>Medical Science Monitor</i> , 2019, 25, 5518-5524.	1.1	3
8	Serum EGFR gene mutation status via second-generation sequencing and clinical features of patients with advanced lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 3551-3558.	0.5	2
9	Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects. <i>Oncotarget</i> , 2016, 7, 62619-62626.	1.8	14